样式: 排序: IF: - GO 导出 标记为已读
-
Survival Benefits of Ganoderma Lucidum in Early-stage Triple-negative Breast Cancer: A Real World Study Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-22 Baohong Jiang, Na Li, Wei Du, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Hongbo Zhu, Feng Ye
Background:: Ganoderma lucidum extracts are widely used as adjuvants in the treatment of triple-negative breast cancers (TNBC) in China. However, its clinical value in TNBC remains unclear. Therefore, we investigated the clinical effect of Ganoderma lucidum spore powder (GLSP) on prognosis in patients with early-stage TNBC in this study. Methods:: A total of 388 patients who were diagnosed with TNBC
-
UBE2L3 Promotes Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-22 Xiwu Zhao, Guoqiang Shan, Deguo Xing, Hongwei Gao, Zhenggang Xiong, Wenpeng Hui, Mingzhi Gong
Background:: Osteosarcoma is a highly invasive bone marrow stromal tumor with limited treatment options. Oxidative stress plays a crucial role in the development and progression of tumors, but the underlying regulatory mechanisms are not fully understood. Recent studies have revealed the significant involvement of UBE2L3 in oxidative stress, but its specific role in osteosarcoma remains poorly investigated
-
Metformin Inhibits NLRP3 Inflammasome Expression and Regulates Inflammatory Microenvironment to Delay the Progression of Colorectal Cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-13 Gaojie Liu, Feixiang Wang, Yanlin Feng, Hongsheng Tang
Background: Colorectal cancer is a common malignant tumor, with about one million people diagnosed with it worldwide each year. Recent studies have found that metformin can inhibit the production of inflammatory factors and regulate the polarization of immune cells. However, whether metformin can regulate the inflammatory microenvironment and delay the progression of colorectal cancer by inhibiting
-
Mechanisms of Anti-PD Therapy Resistance in Digestive System Neoplasms Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-02 Yuxia Wu, Xiangyan Jiang, Zeyuan Yu, Zongrui Xing, Yong Ma, Huiguo Qing
: Digestive system neoplasms are highly heterogeneous and exhibit complex resistance mechanisms that render anti-programmed cell death protein (PD) therapies poorly effective. The tumor microenvironment (TME) plays a pivotal role in tumor development, apart from supplying energy for tumor proliferation and impeding the body's anti-tumor immune response, the TME actively facilitates tumor progression
-
TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-02 Lu Miao, Buze Chen, Li Jing, Tian Zeng, Youguo Chen
Background: Aberrant expression of tumor protein D52 (TPD52) is associated with some tumors. The role of TPD52 in uterine corpus endometrial carcinoma (UCEC) remains uncertain. Objective: We aimed to investigate the involvement of TPD52 in the pathogenesis of UCEC. Methods: We employed bioinformatics analysis and experimental validation in our study. Results: Our findings indicated that elevated TPD52
-
Regulating Lipid Metabolism via Mitochondrial Dynamics in Tongue Squamous Cell Carcinoma Cancer Stem Cells Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-02 Fan Wu, Suling Chen, Siqi Ren, Ruixin Wang, Yongmei Tan, Rongxi Chen, Bowen Li, Haotian Cao, Jinsong Li
Background: Cancer stem cells (CSCs) are a sub-population of cancer cells present in many kinds of malignant tumors that have the potential for self-proliferation and differentiation. These cells have been demonstrated as the main cause of tumor recurrence and metastasis. Strong evidence indicates that CSCs prefer reprogrammed fatty acid β-oxidation over oxidative phosphorylation for sustaining energy
-
SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/mTOR Signaling Pathways Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-02 Jinling Zhou, Jian Luo, Rizhi Gan, Limin Zhi, Huan Zhou, Meixian Lv, Yinmei Huang, Gang Liang
Background: Saponin of Schizocapsa plantaginea Hance I (SSPH I),a bioactive saponin found in Schizocapsa plantaginea, exhibits significant anti-proliferation and antimetastasis in lung cancer. Objective: To explore the anti-metastatic effects of SSPH I on non-small cell lung cancer (NSCLC) with emphasis on epithelial-mesenchymal transition (EMT) both in vitro and vivo. Methods: The effects of SSPH
-
Screening of Candidate Inflammatory Markers of Epithelial Cells in Hepatocellular Carcinoma Based on Integration Analysis of TCGA/ICGC Databases and Single-cell Sequencing Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-02-01 Zupin Huang, Zhuokai Li, Xinliang Lv, Wei Tan
Background: Hepatocellular Carcinoma (HCC) is closely linked to inflammatory reactions, with chronic liver diseases acting as major risk factors. In the inflammatory microenvironment, repeated damage and repair of liver cells lead to genetic mutations, abnormal proliferation, and tumorigenesis. Objective: This study aimed to investigate the expression profile of specific cell clusters under inflammatory
-
Statin Use and Hepatocellular Carcinoma Risk: A Comprehensive Meta- Analysis and Systematic Review Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-29 Mahmood Reza Hashemi Rafsanjani, Rasoul Rahimi, Saeid Heidari-Soureshjani, Mohammad Darvishi, Omid-Ali Adeli, Saber Abbaszadeh
Background: Hepatocellular Carcinoma (HCC) is a public health problem around the world. Several studies have investigated the association between statin use and the risk of HCC, however, more studies are needed in this field. Objectives: This systematic review and meta-analysis aimed to investigate the relationship between statin use and HCC risk. Methods: Systematic searches of Web of Science, Scopus
-
Updated Progress on Mass Spectrometry Imaging and its Application in Cancer Treatment and Drug Discovery Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-25 Mingyue Li, Jingna Zhou, Tingting Zhang, Jingyang Lu, Yajie Wang, Junyu Liu, Xiaoyu Zhang, Haixia Chen
Background: Mass spectrometry imaging (MSI) is an imaging method based on mass spectrometry technology that can simultaneously visualize the spatial distribution of various biological molecules. The use of MSI in cancer detection and drug discovery has been extensively investigated in recent years. Objective: This review aims to summarize the latest advances of MSI and its specific applications in
-
Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-24 Duanhao Gong, Jia Gu, Kuangguo Zhou, Wei Huang
Background:: The tumor burden before chimeric antigen receptor T (CAR-T) cell therapy was one of the critical factors affecting the prognosis of lymphoma. It was a challenge to effectively reduce the tumor burden of relapsed/refractory large B-cell lymphoma with p53 mutation. Objective:: Here, we have presented a case of relapsed/refractory large B-cell lymphoma with p53 mutation being controlled by
-
Targeting the Key Signaling Pathways in Breast Cancer: From Molecular Mechanism to Therapeutic Interventions Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-22 Deepika Singh, Ankit Sahoo
: Breast cancer is a public health issue in developing and developed countries. Nowadays, the concept of BCSC (breast cancer stem cell) is gaining popularity among oncology researchers. The breast cancer stem cell is a tiny cell fraction inside the tumor mass that shows features that look like stem cells that are implicated in the genesis, recurrence, and metastasis of breast cancer tumors. Extracellular
-
Curcumin Inhibits the Growth of Hepatocellular Carcinoma via the MARCH1-mediated Modulation of JAK2/STAT3 Signaling Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-21 Jiaqi Su, Xianbing Liu, Xiaoyue Zhao, Hongjie Ma, Yuzhu Jiang, Xu Wang, Peiyuan Wang, Mingdong Zhao, Xuemei Hu
Background: Curcumin has been reported to have anti-hepatocellular carcinoma (HCC) effects, but the underlying mechanism is not well known. Objectives: To investigate whether membrane-associated RING-CH 1 (MARCH1) is involved in the curcumin-induced growth suppression in HCC and its underlying molecular mechanism. A few recent patents for curcumin for cancer are also reviewed in this article. Methods:
-
Causal Relationships of Chronic Constipation and Irritable Bowel Syndrome with Digestive Tract Cancers: A Mendelian Randomization Study Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-21 Rencai Fan, Jiaqi Zhang, Jiaofeng Shen, Chenkai Mao, Shicheng Li, Zhixiang Zhuang
Background: Chronic constipation and irritable bowel syndrome (IBS) manifest as prevalent gastrointestinal disorders, while digestive tract cancers (DTCs) present formidable challenges to global well-being. However, extant observational studies proffer uncertain insights into potential causal relationships of constipation and IBS with susceptibility to DTCs. Methods: We executed Mendelian randomization
-
Protective Assessment of Novel (Bncs Formulation) against Brain Tumor Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-17 Anuradha Mishra, Afza Ahmad, Irfan Ahamad Ansari, Rohit Kumar Tiwari
Background: Oxidative stress refers to non-homeostatic elevation within intracellular reactive oxygen species (ROS) levels and is associated with several neuro-related pathological conditions. Diclofenac is a commonly prescribed non-steroidal anti-inflammatory drug (NSAID) for treating aches and pain by reducing inflammation. Diclofenac is also associated with the induction of apoptotic cell death
-
Identification of Breast Cancer Immune-related Prognostic Characteristics in Tumor Microenvironment Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-12 Zhenning Tang, Ling Li, Xiaoying Huang, Yinbing Zhao, Qingyuan Liu, Chaolin Zhang
Background: Accumulated evidence suggest that tumor microenvironment (TME) plays a crucial role in breast cancer (BRCA) progression and therapeutic effects. Objective: This study aimed to characterize immune-related BRCA subtypes in TME, and identify genes with prognostic value. Methods: RNA sequencing profiles with corresponding clinical data from The Cancer Genome Atlas (TCGA) database of BRCA patients
-
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-12 Liu Yangjie, Cao Peng, Faiza Ahad, Syed Aqib Ali Zaidi, Tobias Achu Muluh, Qiuxia Fu
: Chimeric antigen receptor T-cells, known as CAR-T cells, represent a promising breakthrough in the realm of adoptive cell therapy. These T-cells are genetically engineered to carry chimeric antigen receptors that specifically target tumors. They have achieved notable success in the treatment of blood-related cancers, breathing new life into this field of medical research. However, numerous obstacles
-
Differentiation of Acute Leukemia Cells Including Cells with MLL-AF4 Rearrangements Induced by Jiyuan Oridonin A Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-11 Xueming Li, Fenglian Zhang, Yu Ke, Hongmin Liu, Zhenbo Hu, Liuya Wei
Background:: Chromosomal rearrangements involving the Mixed lineage leukemia (MLL) gene are observed in acute leukemia (AL) patients, which have poor prognosis, especially in infants. Hence, there is still a challenge to develop other effective agents to treat AL with MLL rearrangements (MLLr). MLL has been shown to rearrange with partner genes, of which the most frequently observed are AF4 and AF9
-
TENT5A Increases Glioma Malignancy and Promotes its Progression Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-11 Jiali Hu, Lei zeng, Ronghuan Hu, Dan Gong, Mengmeng Liu, Jianwu Ding
Background:: Recent studies reported that terminal nucleotidyltransferase 5A (TENT5A) is highly expressed in glioblastoma and associated with poor prognosis. In this work, we aim to specify the expression level of TENT5A in different grades of glioma and explore its role in glioma progression. Methods:: GEPIA online tools were used to perform the bioinformatic analysis. qRT-PCR, Western blot, and
-
Comprehensive Bioinformatic Analysis Reveals an Autophagy-related Gene Signature for Predicting Outcome, Immune Status, and Drug Sensitivity in Hepatocellular Carcinoma Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-11 Peng Liu, Yan Zhou, Shun Zeng, Xiangjuan Chen
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, but molecular complexity and tumor heterogeneity make predictive models for HCC prognosis ineffective. Many recent studies have suggested that autophagy is important in tumor progression. Using autophagy-related genes (ARGs), we attempted to create a novel signature for individual prognosis prediction in
-
Increased SLC7A3 Expression inhibits Tumor Cell Proliferation and Predicts a Favorable Prognosis in Breast Cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-11 Lifang He, Yue Xu, Jiediao Lin, Stanley Lin, Yukun Cui
Background: Arginine plays significant and contrasting roles in breast cancer growth and survival. However, the factors governing arginine balance remain poorly characterized. Objective: We aimed to identify the molecule that governs arginine metabolism in breast cancer and to elucidate its significance. Methods: We analyzed the correlation between the expression of solute carrier family 7 member 3
-
Exosome-Derived Cargos in Immune Microenvironment in Esophageal Carcinoma: A Mini-Review Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2024-01-04 Yakun Zhang, Xiaoyan Sun, Yan Guan, Ying Sun
: Esophageal carcinoma, a lethal malignancy with limited treatment options and poor prognosis, necessitates understanding its underlying mechanisms and identifying novel therapeutic targets. Recent studies have highlighted the critical role of the immune microenvironment in esophageal carcinoma, particularly the interplay between tumor cells and immune cells mediated by exosomes and their cargos. Exosomes
-
Matrix Metalloproteinase-2 (MMP-2): As an Essential Factor in Cancer Progression Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-12-27 R. Aishwarya Reddy, M. Sai Varshini, R. Suresh Kumar
: The development of cancer has been a multistep process involving mutation, proliferation, survival, invasion, and metastasis. Of all the characteristics of cancer, metastasis is believed to be the hallmark as it is responsible for the highest number of cancer-related deaths. In connection with this, Matrix metalloproteinases (MMPs), that has a role in metastasis, are one of the novel therapeutic
-
Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-11-10 Rong-Yan Guan, Xing-Ru Tang, Zou-Fang Huang, Jun Du, Xue-Hang Fu, Guang Lu, Wei-Wei Mou
Introduction:: Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric monoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness in treating SMZL. Given the low incidence and selection of treatment
-
Intracholecystic Papillary-tubular Neoplasm (ICPN) of the Gallbladder: A Case Report Focusing on an Unexpected Pathological Finding Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-10-27 Antonio Pesce, Valentina Sani, Alba Gaban, Nicolò Fabbri, Massimo Tilli, Roberta Gafà, Carlo Vittorio Feo
Background: Intracholecystic papillary neoplasms (ICPNs) represent a rare benign entity characterized by intraluminal polypoid lesions in the gallbladder. The incidence of ICPNs ranges from 0.4% to 0.61% in all gallbladder specimens. Case Presentation: In this report, we present a case of a young Caucasian woman who underwent elective laparoscopic cholecystectomy due to gallbladder polyps. The histological
-
Upregulation of M6A Reader HNRNPA2B1 Associated with Poor Prognosis and Tumor Progression in Lung Adenocarcinoma Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-10-19 Wei Wang, Shengwei Li
Background: Lung cancer is the most prevalent malignancy worldwide, and lung adenocarcinoma (LUAD) accounts for a substantial proportion of all cases. N6-methyladenosine (m6A) is the most frequent post-transcriptional modification in mRNAs that also plays a role in cancer development. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) is a reader of m6A modification, which can affect tumor invasion
-
The Clinical Significance and Prognostic Value of ALDH1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-10-11 Dong Li, Yu Cao, Cheng-Wen Luo, Li-ping Zhang, Ying-Bo Zou
Background: The results of the association between aldehyde dehydrogenase 1 (ALDH1) expression and prognosis of non-small cell lung cancer (NSCLC) are contradictory. We conducted this meta-analysis to investigate the clinical significance and prognostic value of ALDH1 in NSCLC. Methods: The databases PubMed, Web of Science, EMBASE, the Cochrane Library, Wanfang, and CNKI were systematically queried
-
Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-Seq and Bulk RNA-Seq Analysis in GC Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-10-09 Guoxiang Guo, Zhifeng Zhou, Shuping Chen, Jiaqing Cheng, Yang Wang, Tianshu Lan, Yunbin Ye
Background:: Cellular senescence (CS) is thought to be the primary cause of cancer development and progression. This study aimed to investigate the prognostic role and molecular subtypes of CS-associated genes in gastric cancer (GC). Methods:: The CellAge database was utilized to acquire CS-related genes. Expression data and clinical information of GC patients were obtained from The Cancer Genome Atlas
-
CK2B is a Prognostic Biomarker and a Potential Drug Target for Hepatocellular Carcinoma Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-10-02 huiru Dai, Minling Liu, Yuxi Pan, Tingwei Li, Yihang Pan, Zhesheng Chen, Jing Li, Yuchen Liu, Shuo Fang
Background: Although casein kinase II subunit beta (CK2B) was previously reported to be involved in human cancers, such as hepatocellular carcinoma (HCC), there has been no systematic assessment of CK2B in HCC. Objective: To assess the potential function of CK2B as a prognostic biomarker and possible druggable target in HCC. Methods: The Cancer Genome Atlas database was accessed to investigate the
-
Research progress on the anticancer activity of plant polysaccharides Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-19 Qiaoyan Liu, Bo Song, Sen Tong, Qiuqiong Yang, Huanhuan Zhao, Jia Guo, Xuexia Tian, Renjie Chang, Junzi Wu
: Tumor is a serious threat to human health, with extremely high morbidity and mortality rates. However, tumor treatment is challenging, and the development of antitumor drugs has always been a significant research focus. Plant polysaccharides are known to possess various biological activities. They have many pharmacological properties such as immunomodulation, antitumor, antiviral, antioxidative,
-
TGF-β score based on silico analysis can robustly predict prognosis and immunological characteristics in lower-grade glioma: the evidence from multicenter studies Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-18 Weizhong Zhang, Zhiyuan Yan, Feng Zhao, Qinggui He, Hongbo Xu
Introduction: Nowadays, mounting evidence shows that variations in TGF-β signaling pathway-related components influence tumor development. Current research has patents describing the use of anti-TGF-β antibodies and checkpoint inhibitors for the treatment of proliferative diseases. Importantly, TGF-β signaling pathway is significant for lower-grade glioma (LGG) to evade host immunity. Loss of particular
-
Chebulinic Acid: An Incipient Anticancer Agent Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-11 Aashima, Mehak Rathi, Shilpi, Akash, Kamaljeet Kaur, Priyanka Kriplani, Kumar Guarve
Background: Terminalia chebula (T. chebula) comprising chebulinic acid as its principle active constituent is used to cure various diseases. T. chebula and chebulinic acid are used as antimicrobial, antioxidant, antidiabetic, anti-inflammatory, hepatoprotective, antimutagenic, radioprotective, cardioprotective, antiproliferative, antiarthritic, anticaries, and so on. Objective: The objective of this
-
Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-11 Zhengwei Chen, Guoxiong Cheng
Background: Gastric cancer (GC) is a common gastrointestinal tumor with high morbidity and mortality. Fatty acid metabolism (FAM) contributes to GC development. Patents have been issued for the use of compositions comprising fatty acid analogues for the treatment of many clinical conditions. However, its clinical significance and its relationship with tumor-related mutations have not been thoroughly
-
Comprehensive genomic analysis of puerarin in inhibiting bladder urothelial carcinoma cell proliferation and migration Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-11 Yu-yang Ma, Ge-jin Zhang, Peng-fei Liu, Ying Liu, Ji-cun Ding, Hao Xu, Lin Hao, Deng Pan, Hai-luo Wang, Jing-kai Wang, Peng Xu, Zhen-duo Shi, Kun Pang
Background: Bladder urothelial carcinoma (BUC) ranks second in the incidence of urogenital system tumors, and the treatment of BUC needs to be improved. Puerarin, a traditional Chinese medicine (TCM), has been shown to have various effects such as anti-cancer effects, the promotion of angiogenesis, and anti-inflammation. This study investigates the effects of puerarin on BUC and its molecular mechanisms
-
Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-09-01 Chang Zheng, Hanbin Guo, Yongpan Mo, Guowen Liu
Background: Breast cancer accounts for over 1.8 million new cases worldwide annually, and prompt diagnosis and treatment are imperative to prevent mortality. Necroptosis, a form of programmed cell death, is thought to be a critical pathway for cancer cell apoptosis, yet, its relationship with breast cancer progression and molecular mechanisms remains largely unexplored. Objectives: Our study aims to
-
Identification of the Roles of Coagulation-Related Signature and its Key Factor RABIF in Hepatoma Cell Malignancy Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-08-30 Yanying Chen, Yin Li, Bingyi Zhou
Background: Hepatoma is a high morbidity and mortality cancer, and coagulation is a potential oncogenic mechanism for hepatoma development. Objective: In this study, we aimed to reveal the role of coagulation in hepatoma. Methods: We applied the LASSO to construct a coagulation-related risk score (CRS) and a clinical nomogram with independent validation. The heterogeneity of various aspects, including
-
Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-08-21 Yalei Wang, Shuo Cheng, Huawei Zhang, Yali Zhang, Chengcheng Ding, Tiantian Peng, Weihang Chen, Ke Yang, Jiani Zhang, Yan Tan, Xu Wang, Zhaoheng Liu, Peng Wei, Miao Jiang, Qian Hua
Background: Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), frequently causes side effects when used to treat non-small cell lung cancer. Objective: The purpose of this experiment was to investigate the side effect of gefitinib on the skin and colon of mice. Methods: Male Balb/c nu-nu nude mice aged 4-5 weeks were used as xenograft tumor models, and gefitinib at
-
1,3,4-Oxadiazoles as Anticancer Agents: A Review Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-08-10 Greesh Kumar, Rajnish Kumar, Avijit Mazumder, Salahuddin, Upendra Kumar
Among the deadliest diseases, cancer is characterized by tumors or an increased number of a specific type of cell because of uncontrolled divisions during mitosis. Researchers in the current era concentrated on the development of highly selective anticancer medications due to the substantial toxicities of conventional cytotoxic drugs. Several marketed drug molecules have provided resistance against
-
Natural STAT3 inhibitors for cancer treatment: A Comprehensive Literature Review Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-08-03 Seyed Mahdi Zarezadeh, Amir Mohammad Sharafi, Gisou Erabi, Arefeh Tabashiri, Navid Teymouri, Hoda Mehrabi, S. Amirhossein Golzan, Arezoo Faridzadeh, Zahra Abdollahifar, Nafiseh Sami, Javad Arabpour, Zahra Rahimi, Arina Ansari, Mohammadreza Abbasi, Nima Azizi, Amirhossein Tamimi, Mohadeseh Poudineh, Niloofar Deravi
: Cancer is one of the leading causes of mortality and morbidity worldwide, affecting millions of people physically and financially every year. Over time, many anticancer treatments have been proposed and studied, including synthetic compound consumption, surgical procedures, or grueling chemotherapy. Although these treatments have improved the daily life quality of patients and increased their survival
-
Predictive Modelling of Overall Survival in Adult Patients with Primary Diffuse Large B-cell Lymphoma of the Breast Using the Surveillance, Epidemiology, and End Results (SEER) Database Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-08-01 Yishuai Liu, Haifeng Han, Hong Wei, Xinlong Wang, Zhaotang Luan, Kun Jiang
Objective: We aimed to identify critical clinical features to develop an accurate webbased prediction model for estimating the overall survival (OS) of primary breast diffuse large Bcell lymphoma (PB-DLBCL) adult patients. Methods: We first included all PB-DLBCL cases with available covariates retrieved from the Surveillance, Epidemiology, and End Results database. We sequentially performed univariate
-
Development of a Novel Lipid Metabolism-related Gene Prognostic Signature for Patients with Colorectal Cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-07-31 Jing Zhan, Wei Cen, Junchang Zhu, Yunliang Ye
Background: The purpose of this study was to explore the expression profiles of lipid metabolism-related genes in patients with Colorectal Cancer (CRC). Methods: The lipid metabolism statuses of CRC patients from The Cancer Genome Atlas (TCGA) were analyzed. Risk characteristics were constructed by univariate Cox regression and minimum Absolute contraction and Selection Operator (LASSO) Cox regression
-
From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-07-13 Xue-Hang Fu, Rong-Yan Guan, Zoufang Huang, Yun Li, Guang Lu, Wei-Wei Mou, Jun Du
Background: As the second most prevalent hematologic malignancy, multiple myeloma (MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly involving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically heterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting clonal heterogeneity throughout all stages
-
The Causal Effects of Cholelithiasis on Acute Pancreatitis and Pancreatic Cancer: A Large Sample Size Mendelian Randomization Analysis Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-26 Moshi Rao, Xiaoshun Ai, Zijian Huang
Background: The aim of two-sample Mendelian randomization (MR) with a large sample size was to explore the causal cholelithiasis impact on acute pancreatitis and pancreatic cancer. Methods: We performed the two-sample MR analysis with two models. Publicly available summary- level information for cholelithiasis was acquired from the Genome-Wide Summary Association Studies (GWAS) of FinnGen Biobank.
-
Unlocking Delivery Strategies for mRNA Therapeutics Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-23 Zhiyuan Luo, Yangchao Chen
mRNA emerged as an attractive therapy modality with the development of mRNA structure engineering techniques and delivery platforms. mRNA therapeutics, applied for vaccine therapy, protein replacement therapy, and chimeric antigen receptor (CAR) T cell-based therapy, has shown huge potential in treating a wide range of diseases, such as cancer and rare genetic diseases, with successful and exciting
-
Integrated Single-cell and Bulk RNA Sequencing Analysis Cross Talk between Ferroptosis-related Genes and Prognosis in Oral Cavity Squamous Cell Carcinoma Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-19 Tianjun Lan, Siqi Ren, Huijun Hu, Ruixin Wang, Qian Chen, Fan Wu, Qiuping Xu, Yanyan Li, Libin Shao, Liansheng Wang, Xin Liu, Haotian Cao, Jinsong Li
Background: Ferroptosis is a new type of programmed apoptosis and plays an important role in tumour inhibition and immunotherapy. Objective: In this study, we aimed to explore the potential role of ferroptosis-related genes (FRGs) and the potential therapeutic targets in oral cavity squamous cell carcinoma (OCSCC). Methods: The transcription data of OCSCC samples were obtained from the Cancer Genome
-
PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-19 Min Xiong, Zhenghe Chen, Chao Zhou, Xiaochun Yang, Wanming Hu, Yongluo Jiang, Rongliang Zheng, Wei Fan, Yonggao Mou, Xiaoping Lin
Background: Glioma is characterized by a high recurrence rate, while the results of the traditional imaging methods (including magnetic resonance imaging, MRI) to distinguish recurrence from treatment-related changes (TRCs) are poor. Prostate-specific membrane antigen (PSMA) (US10815200B2, Deutsches Krebsforschungszentrum, German Cancer Research Center) is a type II transmembrane glycoprotein overexpressed
-
The FJQR Has Synergistic Effect with Fluoropyrimidine in the Maintenance Treatment for HER-2 Negative Gastric Cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-09 Fanming Kong, Lu Zhao, Na Wang, Dou Zhang, Ziwei Wang, Qingyun Mei, Yongchao Yu, Yingjie Jia
Introduction: Maintenance therapy aimed to strengthen the first-line chemotherapy and improve quality of life is needed for gastric cancer (GC). Currently, many clinical studies have confirmed the important role of fluoropyrimidine in the maintenance stage. Our team has created patented prescriptions “Fuzheng jiedu Quyu Method” recipe (FJQR), which was considered as an adjuvant therapeutic scheme (reduce
-
Prognostic Value of Fatty Acid Metabolism-related Genes in Patients with Bladder Cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-06-09 Qiuzheng Huang, Zhijia Li, Chao Liu
Introduction: This study aimed to explore the expression profiles of fatty acid metabolism- related genes (FAMRGs) in patients with bladder cancer (BLCA). Methods: The corresponding clinicopathological features of BLCA patients and RNA sequencing data were downloaded from TCGA and GSE13507. Univariate Cox regression was used to determine the prognostic value of FRGS in BLCA patients. LASSO regression
-
LncRNA FAM83H-AS1 Contributes to the Radio-resistance and Proliferation in Liver Cancer through Stability FAM83H Protein Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-15 Xiaocong Jiang, Yuhong Lan, Yingchun Zhang, Yuhong Dong, Ting Song
Background: Liver cancer (LC) is one of China's most common malignant tumors, with a high mortality rate, ranking third leading cause of death after gastric and esophageal cancer. Recent patents propose the LncRNA FAM83H-AS1 has been verified to perform a crucial role in the progression of LC. LncRNA FAM83H-AS1 has been verified to perform a crucial role in the progression of LC. However, the concrete
-
Human Chorionic Gonadotropin Regulates the Smad Signaling Pathway by Antagonizing TGF-β in Giant Cell Tumor of Bone Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-11 Tangbing Xu, Shenglin Xu, Guangwen Ma, Jun Chang, Chi Zhang, Ping Zhou, Chao Wang, Pengfei Xu, Junjun Yang, Yong Hu, Yunfeng Wu
Background: Giant cell tumor of bone (GCTB) is a locally aggressive bone tumour aggravated by stromal cell proliferation and metastasis. Objective: We investigated the mechanism of action of human chorionic gonadotropin (HCG) in mediating GCTB proliferation and invasion. Methods: The expression of HCG was quantified using quantitative real-time PCR. After the primary stromal cells were isolated and
-
KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-11 Pankaj Kumar Tripathi, Khushi R. Mittal, Nandini Jain, Naveen Sharma, Chakresh Kumar Jain
One of the major disturbing pathways within cancer is “The Kirsten rat sarcoma viral oncogene homolog (KRAS) pathway”, and it has recently been demonstrated to be the most crucial in therapies and diagnostics. KRAS pathway includes numerous genes. This multi-component signaling system promotes cell growth, division, survival, and death by transferring signals from outside the cell to its interior.
-
A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022) Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-10 Pinky Gehlot, Vivek K. Vyas
Highly proliferating cells, such as cancer cells, are in high demand of pyrimidine nucleotides for their proliferation, accomplished by de novo pyrimidine biosynthesis. The human dihydroorotate dehydrogenase (hDHODH) enzyme plays a vital role in the rate-limiting step of de novo pyrimidine biosynthesis. As a recognised therapeutic target, hDHODH plays a significant role in cancer and other illness
-
A Synergistic Combination of Oleanolic Acid and Apatinib to Enhance Antitumor Effect on Liver Cancer Cells and Protect against Hepatic Injury Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-05 Juan Ren, Jun Yan, Faisal Raza, Hajra Zafar, Haopeng Wan, Xue Chen, Qingrong Cui, Haiyang Li, Xiangqi Wang
Background: As a pentacyclic triterpenoid, OA (oleanolic acid) has exhibited antiinflammatory, immunomodulatory and antitumor effects. VEGFR-2 (vascular endothelial cells receptor-2) tyrosine kinase activity could be inhibited by apatinib, a small-molecule antiangiogenic agent. Objective: Thus, this study sought to investigate the mechanism underlying the synergistic antitumor activity of combined
-
Competitive Effect of Overexpressed C-terminal of Snail-1 (CSnail) in Control of the Growth and Metastasis of Melanoma Cells Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-03 Sadegh Paydari Rostami, Negar Moghare Dehkordi, Yazdan Asgari, Mohammad Reza Bolouri, Nasrin Shayanfar, Reza Falak, Gholam Ali Kardar
Background: Epithelial-to-mesenchymal transition (EMT) plays a role in the invasion and metastasis of cancer cells. During this phenomenon, Snail can promote tumor progression by upregulating mesenchymal factors and downregulating the expression of pro-apoptotic proteins. Objective: Therefore, interventions on the expression rate of Snails may show beneficial therapeutic applications. Methods: In this
-
Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-05-03 Guixian Wu, Qian Chen, Dongqing Lv, Ling Lin, Jing Huang
Background: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been proven a long-lasting treatment effect in pulmonary adenocarcinoma, most patients still progressed within one year due to the acquired resistance. Complex mutations of rare rare sites after acquiring resistance are rarely reported in pulmonary adenocarcinoma. Case Presentation: A 62-year-old woman
-
Co-delivery of siAPE1 and melatonin by 125I-loaded PSMA-targeted nanoparticles for the treatment of prostate cancer Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-04-20 Zhen-Duo Shi, Kun Pang, Ying Liu, Lin Hao, Yang Dong, Bing-Zheng Dong, Xin-Lei Wang, Xing Liu, Zheng-Xiang Hu, Gao-Chuan Fang, Guang-Yue Wang, Jia-Xin Qin
Background: Both apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) inhibition and melatonin suppress prostate cancer (PCa) growth. This study evaluated the therapeutic efficiency of self-assembled and prostate-specific membrane antigen (PSMA)-targeted nanocarrier loading 125I radioactive particles and encapsulating siRNA targeting APE1 (siAPE1) and melatonin for PCa. Methods: The linear polyarginine
-
Chlorogenic Acid Inhibits Proliferation, Migration and Invasion of Pancreatic Cancer Cells via AKT/GSK-3β/β-catenin Signaling Pathway Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-04-20 Xiaoliang Chen, Binyu Liu, Jiale Tong, Jianing Bo, Miao Feng, Lili Yin, Xiukun Lin
Background: Chlorogenic acid (CA, United States Patent No. 10772340), a natural biologically active food ingredient, displays potent antitumor activity against a variety of cancer cells. However, the mechanism underlying its anticancer effect is not well elucidated. Objective: In the present study, we hope to dissect the mechanism underlying the anticancer effects of CA in pancreatic cancer cells.
-
Circ_0070203 Promotes Epithelial-mesenchymal Transition in Ovarian Serous Cystadenocarcinoma through miR-370-3p/TGFβR2 Axis Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-04-11 Qiong Tang, Huiting Wen, Haoyue Hu, Xiaoli Chen, Shuxiu Xu, Li Fan, Longyang Liu, Jing Li
Introduction: Circular RNAs (circRNAs) are important biological molecules associated with the pathogenesis of multiple cancers. Objective: This work aimed to investigate the function and molecular mechanism of circ_0070203 in high-grade serous ovarian cystadenocarcinoma (HGSOC). Methods: circRNA microarray was conducted to detect the circ_0070203 expression in HGSOC tissues. Bioinformatics analysis
-
New 1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-2-phenylisoquinoline-1(2H)-ones as Phosphoinositide 3-kinase Inhibitors for Treating Cancer and Other Diseases Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-03-15 Surya K. De
The patent describes novel useful compounds, such as PI3K protein kinase inhibitors, in particular as PI3K delta (δ) and/or gamma (γ) protein kinase modulators. The present disclosure also provides methods for preparing PI3K protein kinase inhibitors, pharmaceutical compositions containing them, and methods of treatment, prevention, and amelioration of PI3K kinase-mediated diseases, and disorders.
-
A Descriptive Review of Cannabis sativa Patents for Cancer Treatment Recent Pat. Anti-Cancer Drug Discov. (IF 2.8) Pub Date : 2023-03-13 Isabela Fernandes Pereira, Ana Maria Santos Oliveira, Anamaria Mendonça Santos, Denis de Melo Soares, Mairim Russo Serafini, Izabel Almeida Alves
Background: Cannabis use for tumor treatment has been explored in several areas, and its potential for tumor remission is currently being studied after the discovery of the endogenous cannabinoid. Objective: The study aimed to conduct a critical patent review to identify and explore the latest advances and therapeutic strategies using Cannabis to treat cancer. Methods: The research was carried out